Core Viewpoint - Novo Nordisk's stock has dropped approximately 18% following a weaker outlook for fiscal 2026, indicating challenges in sales growth and competitive pressures in the obesity and diabetes markets [1]. Novo Nordisk 2026 Guidance - Novo Nordisk anticipates a sales decline of -5% to -13% at constant exchange rates (CER) for 2026, excluding $4.2 billion from the reversal of 340B provisions [2]. - The sales outlook is affected by lower realized prices due to the "Most Favoured Nations" agreement in the U.S., patent expirations for semaglutide in certain markets, and increased competition [2]. Revenue from Weight Loss Drugs - Sales of Novo Nordisk's Ozempic increased by 1% to 31.83 billion Danish kroner (approximately $5.03 billion), while Wegovy sales rose by 17% to 21.86 billion Danish kroner (around $3.46 billion) [4]. - Mounjaro's revenue more than doubled to $7.4 billion, and U.S. Zepbound revenue surged 122% to $4.2 billion [4]. One Year Stock Performance - Over the past year, Novo Nordisk's stock has decreased by around 42%, contrasting with Eli Lilly's stock, which has increased by approximately 34% [5]. - Novo Nordisk's pipeline primarily includes insulin products, heart disease medications, and weight loss drugs, while Eli Lilly has a broader pipeline that includes treatments for cancer, Alzheimer's, and other conditions [5]. Competitive Landscape - Novo Nordisk has significantly increased its U.S. advertising expenditure on Wegovy and Ozempic in 2025, surpassing Eli Lilly as competition intensifies in the obesity and diabetes sectors [6]. - Despite the advancements with Wegovy, Novo Nordisk has struggled to compete with Eli Lilly's Zepbound, which has outperformed Wegovy in weekly new prescriptions this year [6]. Price Action - At the time of publication, Novo Nordisk shares were down 5.85% at $47.35, while Eli Lilly shares were up 9.56% at $1,099.38 [7].

Booming sales for GLP-1RA drugs fuelled a 45% surge in Eli Lilly’s revenue for 2025, cementing the drugmaker’s dominant position in the obesity market. Lilly’s total revenue reached $65.2bn for the full-year 2025, a significant increase from the $45bn recorded in 2024. Shares in Lilly jumped 7.1% to $1075.12 at market open on 4 February from a previous close of $1003.46. Share price continued to rise further to $1100 by 11.15am ET, a 9.62% increase on the 3 February close. Lilly’s market cap is fluctuati ...

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Wednesday's key moments. 1. Stocks were attempting to shake off continued fears that AI disruption could undermine traditional enterprise software companies. Some of the high-multiple names hit hardest in recent sessions, including Club name Microsoft , were trying to bounce Wednesday. Still, the broader market remained under pressure with the S & P 500 and Nasdaq down 1% and 2%, re ...

Market Overview - U.S. stocks showed mixed performance, with the Nasdaq Composite falling over 400 points, while the Dow increased by 0.24% to 49,358.09 and the S&P 500 decreased by 0.89% to 6,856.40 [1] - Energy shares rose by 1.7%, while information technology stocks fell by 2.1% [1] Company Performance - Eli Lilly and Co. saw its stock jump approximately 10% after reporting fourth-quarter adjusted earnings of $7.54 per share, surpassing the consensus estimate of $6.67. The company's sales reached $19.3 billion, exceeding the consensus of $17.96 billion [2] Commodity Market - In commodity trading, oil prices increased by 0.4% to $63.46, while gold prices decreased by 0.5% to $4,909.70. Silver prices rose by 1.6% to $84.615, and copper prices fell by 3.2% to $5.8945 [3] European Market - European shares were mixed, with the eurozone's STOXX 600 gaining 0.03%, while Spain's IBEX 35 Index fell by 0.09%. London's FTSE 100 increased by 0.85%, Germany's DAX slipped by 0.72%, and France's CAC 40 gained 1.01% [4] Asian Market - Asian markets closed higher, with Japan's Nikkei surging by 0.78%, Hong Kong's Hang Seng Index gaining 0.05%, China's Shanghai Composite rising by 0.85%, and India's BSE Sensex increasing by 0.09% [5] Economic Indicators - The ISM Services PMI remained unchanged at 53.8 in January, matching the revised reading from December and exceeding market estimates of 53.5. The S&P Global composite PMI rose to 53.0 in January from a preliminary level of 52.8 and up from December's reading of 52.7 [7] - U.S. crude stocks declined by 3.455 million barrels for the week ending January 30, compared to market estimates of a 2 million-barrel draw [7]

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite falling more than 400 points on Wednesday.The Dow traded up 0.24% to 49,358.09 while the NASDAQ dipped 1.87% to 22,819.29. The S&P 500 also fell, dropping, 0.89% to 6,856.40.Check This Out: How To Earn $500 A Month From Goldman Sachs Stock Ahead Of Q4 EarningsLeading and Lagging SectorsEnergy shares gained by 1.7% on Wednesday.In trading on Wednesday, information technology stocks fell by 2.1%.Top HeadlineEli Lilly and Co. (NYSE:LLY) ...

Eli Lilly (LLY) reported $19.29 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 42.6%. EPS of $7.54 for the same period compares to $5.32 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $17.87 billion, representing a surprise of +7.95%. The company delivered an EPS surprise of +7.88%, with the consensus EPS estimate being $6.99.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and ...

Market Overview - The U.S. stock market is experiencing mixed trading patterns with a notable rotation out of technology giants and into broader market sectors [1] - The S&P 500 has slipped around 0.2% to 0.3%, marking a modest decline for the fourth time in the last five days [2] - The Nasdaq Composite has traded approximately 1% lower, with the Nasdaq 100 specifically seeing a 1.4% loss [2] - The Dow Jones Industrial Average has risen by as much as 389 points, or 0.8%, indicating a shift away from tech stocks towards firms expected to benefit from improving growth prospects [2] Economic Indicators - The yield on 10-year Treasuries has remained steady at 4.28% [3] - Upcoming economic data includes the ADP Employment Change and ISM Services PMI for January, which are crucial for assessing the labor market and services sector [5] - The week will culminate with the U.S. Employment Report on February 6th, which includes non-farm payrolls and average hourly earnings [6] Company-Specific Highlights - Advanced Micro Devices (AMD) shares dropped by as much as 15.7% despite stronger-than-expected profits, indicating high expectations for AI-related companies [9] - Uber Technologies (UBER) fell 3% to 5% after its quarterly results and profit forecast fell short of expectations [10] - Super Micro Computer (SMCI) rallied by 12% to 14% after delivering stronger-than-expected profits [10] - Eli Lilly (LLY) surged by 9.2% after exceeding profit expectations and providing strong guidance, driven by its obesity drugs [11] - Silicon Laboratories (SLAB) shares soared by 51% following the announcement of its acquisition by Texas Instruments for approximately $7.5 billion [13] - Nvidia (NVDA) shares declined 2.8% due to a broad tech sell-off and uncertainty surrounding its OpenAI investment [14]

Market Overview - Pre-market futures have shown a recovery from early lows, influenced by Q4 earnings reports and private-sector job numbers, with the Dow up by 142 points and the S&P 500 up by 10 points, while the Nasdaq is down by 66 points [1] Employment Data - Private-sector payrolls for January reported by ADP came in at +22K, significantly below expectations, and down from a revised +37K the previous month, marking the first back-to-back monthly job gains since April and May of the previous year [2] - Services employment accounted for most of the private-sector hires, with +21K in services compared to only +1K in goods-producing sectors; Healthcare Services led with +74K hires, followed by Financial Services with +14K and Construction with +9K, while Professional & Business Services lost -57K jobs [3] - ADP Chief Economist noted that hiring trends are following consumer demand rather than technology advancements, indicating a disconnect between stock market performance and private-sector job growth [4] Sector Insights - The job gains in the Construction sector may hint at increased labor demand due to data-center buildouts, although it is considered premature to draw definitive conclusions [5] - A new ADP methodology revealed a downward adjustment of -212K fewer hires for the private sector in 2025, reducing total expected hires from +771K in 2024 to +398K in 2025, which may provide a clearer picture of the labor market [6] Earnings Reports - Eli Lilly & Co. reported a +7.9% earnings surprise with earnings of $7.54 per share and revenues of $19.29 billion, driven by strong performance in diabetes and weight loss drugs [8] - AbbVie reported earnings of $2.71 per share, exceeding estimates of $2.66, while Novartis reported $2.03 per share, beating consensus by 4 cents; however, AbbVie shares fell by -3% despite the positive earnings [9] - Phillips 66 reported earnings of $2.47 per share, surpassing expectations of $2.11 and significantly improving from a loss of -$0.15 per share in the same quarter last year, with shares up by +1.3% in pre-market trading [10]

Core Viewpoint - The article discusses the competitive landscape between Eli Lilly and Novo Nordisk, highlighting their positions within the pharmaceutical industry and the potential for investment opportunities in these companies [1]. Group 1: Company Analysis - Eli Lilly (LLY) and Novo Nordisk (NVO) are compared as archrivals in the pharmaceutical sector, with a focus on their market strategies and financial performance [1]. - The analysis aims to identify potential high-return investments, specifically targeting small- and mid-cap companies in the life sciences sector [1]. Group 2: Investment Focus - The author emphasizes a fundamental analysis approach to uncover potential "5–10 baggers," indicating a focus on companies that could significantly increase in value [1]. - The investment strategy includes a focus on early-commercial-stage life sciences companies, insurers, homebuilders, and select consumer-facing businesses [1].

Core Insights - Eli Lilly and Company (LLY) reported strong fourth-quarter 2025 results, with adjusted earnings per share (EPS) of $7.54, exceeding the Zacks Consensus Estimate of $6.99, and a year-over-year earnings increase of 42% [1] - Revenues reached $19.3 billion, a 43% increase year over year, driven by the success of GLP-1 drugs Mounjaro and Zepbound, surpassing the Zacks Consensus Estimate of $17.87 billion [1] Revenue Drivers - Mounjaro generated sales of $7.41 billion, up 110% year over year, exceeding the Zacks Consensus Estimate of $6.65 billion [2] - Zepbound recorded sales of $4.26 billion, a 123% increase year over year, also beating the Zacks Consensus Estimate of $3.87 billion [3] Competitive Landscape - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products, with Novo Nordisk reporting a decline in its Diabetes and Obesity Care segment sales due to competitive pressure from Lilly's offerings [4] - Despite competitive dynamics, Mounjaro and Zepbound are expected to maintain strong demand in 2026 [13] Other Drug Performance - Trulicity generated $1.04 billion in revenue, down 17% year over year, but still beating the Zacks Consensus Estimate of $1.0 billion [5] - Jardiance sales fell 36% to $768 million, missing the Zacks Consensus Estimate of $776 million [5] - Taltz brought in $1.05 billion, up 10% year over year, exceeding the Zacks Consensus Estimate of $955 million [6] - Verzenio generated $1.60 billion, up 3% year over year, but missed the Zacks Consensus Estimate of $1.62 billion [6] Full-Year Performance - For the full year 2025, Eli Lilly's sales rose 45% to $65.2 billion, significantly beating the Zacks Consensus Estimate of $63.54 billion [10] - Adjusted earnings for 2025 were $24.21 per share, an 86% increase year over year, surpassing the Zacks Consensus Estimate of $23.74 [10] 2026 Outlook - Eli Lilly expects 2026 revenues in the range of $80 billion to $83 billion, higher than the Zacks Consensus Estimate of $77.5 billion [11] - EPS for 2026 is projected to be between $33.50 and $35.00, exceeding the Zacks Consensus Estimate of $33.24 [11] Market Reaction - Following the positive quarterly earnings and optimistic 2026 outlook, Lilly's shares rose approximately 9% in pre-market trading [14] - Over the past year, Lilly's stock has increased by 19.2%, outperforming the industry average of 17.1% [14] Strategic Initiatives - Lilly is investing in obesity treatments and has several new molecules in clinical development, including orforglipron, an oral GLP-1 small molecule [16][17] - The company is diversifying its portfolio beyond GLP-1 drugs into cardiovascular, oncology, and neuroscience areas, including recent acquisitions to enhance its capabilities in oral small-molecule therapies [19]